Robert LeBoyer
Stock Analyst at Noble Capital Markets
(1.18)
# 3,761
Out of 5,141 analysts
18
Total ratings
31.25%
Success rate
-0.35%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Robert LeBoyer
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TNXP Tonix Pharmaceuticals Holding | Reiterates: Outperform | $70 | $14.04 | +398.58% | 2 | Mar 20, 2025 | |
| NTRB Nutriband | Initiates: Outperform | $13 | $4.26 | +205.16% | 1 | Jan 22, 2025 | |
| GOVX GeoVax Labs | Maintains: Outperform | $150 → $250 | $1.53 | +16,239.87% | 2 | Aug 19, 2024 | |
| UNCY Unicycive Therapeutics | Initiates: Outperform | $60 | $6.28 | +855.41% | 1 | Feb 14, 2024 | |
| CVKD Cadrenal Therapeutics | Initiates: Outperform | $60 | $6.85 | +776.55% | 1 | Dec 18, 2023 | |
| ELDN Eledon Pharmaceuticals | Initiates: Outperform | $10 | $2.19 | +356.62% | 1 | Sep 27, 2023 | |
| MAIA MAIA Biotechnology | Initiates: Outperform | $14 | $2.08 | +573.08% | 1 | Feb 21, 2023 | |
| LCTX Lineage Cell Therapeutics | Initiates: Outperform | $8 | $1.81 | +341.99% | 2 | Aug 19, 2021 | |
| PSTV Plus Therapeutics | Initiates: Buy | $120 | $0.28 | +43,536.36% | 1 | Jan 25, 2021 | |
| BNTC Benitec Biopharma | Downgrades: Neutral | n/a | $10.64 | - | 1 | Oct 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $12 | $4.12 | +191.26% | 1 | Sep 28, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $9,900,000 | $3.21 | +308,411,114.95% | 1 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $34.30 | - | 1 | Apr 10, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $15 | $3.01 | +398.34% | 2 | Mar 8, 2018 |
Tonix Pharmaceuticals Holding
Mar 20, 2025
Reiterates: Outperform
Price Target: $70
Current: $14.04
Upside: +398.58%
Nutriband
Jan 22, 2025
Initiates: Outperform
Price Target: $13
Current: $4.26
Upside: +205.16%
GeoVax Labs
Aug 19, 2024
Maintains: Outperform
Price Target: $150 → $250
Current: $1.53
Upside: +16,239.87%
Unicycive Therapeutics
Feb 14, 2024
Initiates: Outperform
Price Target: $60
Current: $6.28
Upside: +855.41%
Cadrenal Therapeutics
Dec 18, 2023
Initiates: Outperform
Price Target: $60
Current: $6.85
Upside: +776.55%
Eledon Pharmaceuticals
Sep 27, 2023
Initiates: Outperform
Price Target: $10
Current: $2.19
Upside: +356.62%
MAIA Biotechnology
Feb 21, 2023
Initiates: Outperform
Price Target: $14
Current: $2.08
Upside: +573.08%
Lineage Cell Therapeutics
Aug 19, 2021
Initiates: Outperform
Price Target: $8
Current: $1.81
Upside: +341.99%
Plus Therapeutics
Jan 25, 2021
Initiates: Buy
Price Target: $120
Current: $0.28
Upside: +43,536.36%
Benitec Biopharma
Oct 5, 2020
Downgrades: Neutral
Price Target: n/a
Current: $10.64
Upside: -
Sep 28, 2020
Initiates: Buy
Price Target: $12
Current: $4.12
Upside: +191.26%
Aug 24, 2020
Initiates: Buy
Price Target: $9,900,000
Current: $3.21
Upside: +308,411,114.95%
Apr 10, 2018
Downgrades: Neutral
Price Target: n/a
Current: $34.30
Upside: -
Mar 8, 2018
Initiates: Buy
Price Target: $15
Current: $3.01
Upside: +398.34%